At this year’s ASCO Annual Meeting, researchers presented detailed findings concerning biomarkers and rare subtypes of renal cell carcinoma. Identifying a unique biomarker can be a challenging endeavor, but patients with metastatic RCC are living longer due to the availability of multiple therapeutic options.